What is ipamorelin studied for?

Published August 28, 2026 · Artemis Labs

Ipamorelin is a synthetic five-amino-acid peptide, first described in 1998 by chemists at Novo Nordisk, that binds the receptor the hunger hormone ghrelin normally binds. In published animal and cell research, that binding causes the pituitary gland to release stored growth hormone. What made ipamorelin notable in its own founding paper was not how much growth hormone it released, but what it left alone: unlike the earlier peptides in its class, it did not measurably raise ACTH or cortisol in swine. The research since then covers bone growth, muscle and body weight, gut motility and appetite, almost entirely in rats, mice, ferrets and fish. Two human studies exist, and the only one that measured a clinical outcome found no difference from placebo.

Key findings

• Ipamorelin is a pentapeptide — five residues, Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — with the formula C38H49N9O5 and a molecular weight of 711.9, listed at PubChem CID 9831659, CAS 170851-70-4.
• Its founding paper (PMID 9849822) reported that in swine, “None of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels,” while GHRP-6 and GHRP-2 raised ACTH and cortisol and ipamorelin did not.
• The one randomized, double-blind, placebo-controlled human trial — 114 patients after bowel surgery — reported “no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses” (PMID 25331030).
• In mice, growth hormone secretagogues including ipamorelin increased body fat by a route that did not depend on growth hormone at all (PMID 11162489).

Where did ipamorelin come from?

Ipamorelin was made at Novo Nordisk in Denmark in the late 1990s. The affiliation lines on the original papers place the work in the company’s growth hormone pharmacology and medicinal chemistry departments in Måløv and Bagsværd. Its development code, still listed as a synonym at PubChem, is NNC 26-0161.

The 1998 paper describes how the molecule was found: it came out of a series of compounds built by removing the central Ala-Trp pair from an earlier peptide called GHRP-1. That is a chemistry story, not a biology story, and it matters here for one reason. Ipamorelin was designed to do one job cleanly, and the research that followed has mostly been about testing how cleanly it does it.

How does ipamorelin work in the published research?

There are two separate switches on the pituitary cells that store growth hormone. One responds to growth hormone-releasing hormone, the body’s own signal. The other responds to ghrelin, the hormone the stomach releases when it is empty. Ipamorelin binds the second one — the ghrelin receptor, written in the literature as GHS-R1a.

In isolated rat pituitary cells, ipamorelin released growth hormone with a potency and effect close to GHRP-6, an older peptide in the same family. The 1998 authors then tested the same comparison in anesthetized rats and in conscious swine and got the same answer: similar potency, similar maximum effect. Ipamorelin is not a stronger releaser than what came before it. It is a more selective one.

Two research findings are worth holding onto here, because most writing about this compound skips them. The first is that a 2001 study in mice found ipamorelin increased fat pad weight even in mice that could not make growth hormone properly — the authors concluded that “GHSs increase body fat by GH-independent mechanisms that may include increased feeding.” The second is that the ghrelin receptor is not only in the pituitary. It is in the gut, which is why an entire branch of the ipamorelin literature is about the intestines rather than about hormones at all.

What research areas does the literature actually cover?

Reading every PubMed record for ipamorelin, the work sorts into four groups.

Selectivity and receptor pharmacology. The founding work and its follow-ups, comparing ipamorelin to GHRP-2, GHRP-6 and hexarelin on which hormones move and which do not. This is the deepest and most-cited lane, and it is covered on our page on the selectivity research.

Bone and muscle. Rats given ipamorelin for two weeks to three months: bone length, bone mineral content, muscle tension under steroid treatment, nitrogen balance. The results are more interesting and more qualified than the summaries suggest, and we walk through them on the bone and muscle page.

Gut motility and appetite. Rodent models of the slowed bowel that follows abdominal surgery, plus a ferret chemotherapy model and work on visceral pain. This lane produced the one human efficacy trial.

Detection chemistry. A large share of the ipamorelin literature is not pharmacology at all. It is anti-doping laboratories working out how to find the peptide and its breakdown products in urine — and, in two cases, finding that the material circulating in the market is not quite the molecule it claims to be.

What human research exists?

Two studies. A 1999 pharmacokinetic study gave five ascending infusion rates to healthy male volunteers and measured how quickly the peptide cleared and how growth hormone responded; it reported a terminal half-life of about two hours. It measured hormone levels, not health outcomes.

The second is the trial that matters. In 2014, a multicenter, double-blind, placebo-controlled phase 2 study enrolled 117 patients having bowel resection surgery, of whom 114 were analyzed, to see whether ipamorelin shortened the time to tolerating a solid meal. Median times were 25.3 hours on ipamorelin and 32.6 hours on placebo, and the difference did not reach statistical significance (p = 0.15). The authors’ conclusion is the sentence to remember: ipamorelin “was well tolerated. There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.” The full record is on our page on the human trials.

What the research does not show

No human efficacy has been demonstrated for ipamorelin in any published trial. The one adequately designed test of a clinical outcome did not separate from placebo.

The selectivity finding that defines the compound is an animal and cell result — rat pituitary cells, anesthetized rats, conscious swine. It is a measurement of which hormones moved, not a demonstration that the compound is safe in people, and no page should read it that way.

No long-term exposure data in humans appears anywhere in the published record. And the picture on body weight and fat is not the simple one: the same class of compounds raised body fat in mice through a mechanism that bypassed growth hormone entirely.

Frequently asked questions

Is ipamorelin a hexapeptide?

No. It has five residues. The confusion comes from Aib — α-aminoisobutyric acid — which is not one of the twenty standard amino acids but still counts as a single residue. Pentapeptide is the accurate description.

Is ipamorelin approved as a medicine?

No. Recent review literature classes it among unapproved peptides (PMID 41966639), and the published clinical record consists of the two studies above.

How does it differ from CJC-1295 or sermorelin?

Different receptor. Ipamorelin acts at the ghrelin receptor; CJC-1295, sermorelin and tesamorelin act at the growth hormone-releasing hormone receptor. Our guide to growth hormone research peptides covers how the two families are studied.

Why is so much of the literature about urine testing?

Because anti-doping laboratories need to detect these peptides, and ipamorelin is one of the compounds their methods target. That work is also where the awkward findings about product identity come from — see our page on what forensic laboratories found in seized material.

References

1. Raun K, et al. Eur J Endocrinol. 1998. PMID 9849822.
2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharm Res. 1999. PMID 10496658.
3. Lall S, et al. Biochem Biophys Res Commun. 2001. PMID 11162489.
4. Beck DE, Sweeney WB, McCarter MD. Int J Colorectal Dis. 2014. PMID 25331030.
5. Mendias CL, Awan TM. Sports Med. 2026. PMID 41966639.

Methodology: this page draws on the complete set of PubMed records for ipamorelin, retrieved and read in full on August 28, 2026, together with PubChem’s chemical record. Identity fields were verified the same day.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.